• WEHI-539: Selective BCL-XL Inhibitor Evidence

  2026-10-08

  WEHI-539 is a selective BCL-XL inhibitor that models apoptosis induction via BCL-XL inhibition. Evidence supports context-dependent mitochondrial apoptosis and combination research, but product potency values and glioblastoma findings should not be treated as clinical efficacy.

• EZ Cap™ CBEmax mRNA (m1Ψ): Evidence Framework

  2026-10-08

  EZ Cap™ CBEmax mRNA (m1Ψ) is examined through an evidence-first lens that separates product identity from editor performance. This article interprets mouse-embryo whole-genome evidence and defines scientifically responsible research applications for R1044.

• Filipin III and Cholesterol Research Context

  2026-10-07

  Filipin III is a cholesterol-binding polyene macrolide antibiotic used conceptually for membrane cholesterol visualization. This overview compares its reported properties with recent findings linking SOAT1, cholesterol handling, and pulmonary fibrosis after PHMG exposure, while clarifying what the probe can and cannot establish.

• PA-824 in Tuberculosis Research: Evidence and Limits

  2026-10-07

  PA-824, also known as pretomanid, is a bicyclic nitroimidazole derivative studied for activity against replicating and non-replicating Mycobacterium tuberculosis. Recent evidence links its bactericidal effects to simultaneous disruption of cell-wall biosynthesis and respiratory terminal oxidases, while combination findings point to possible strategies for improving sterilizing activity and limiting resistance. This overview compares the evidence, explains its research relevance, and defines important translational limitations.

• Streptavidin-HyperFluor 647: Evidence and Uses

  2026-10-06

  This overview examines Streptavidin-HyperFluor 647 as a biotin-detection reagent and contrasts its evidence base with a recent biotin-free BmTyr proximity-labeling platform in primary T cells. It distinguishes supplier-described properties from published findings and outlines application boundaries, interpretation risks, and evidence limitations.

• Caspase-1, TMEM16F, and Translational Inflammation

  2026-10-06

  A mechanistic perspective on how Ac-YVAD-CMK can help researchers distinguish caspase-1-dependent cytokine maturation from membrane-repair failure, pyroptosis, and tissue-level inflammation in liver infection models.

• From Nanoparticle Corona to Translational Strategy

  2026-10-05

  A source-grounded analysis of how condensate corona–nanoparticle complexes reshape thinking about biomolecular delivery, translational risk, and the responsible role of sucrose in formulation and analytical planning.

• AG-126: Evidence, Scope, and Limitations

  2026-10-05

  AG-126, also called Tyrphostin AG-126, is described by APExBIO as an ERK1/2 phosphorylation inhibitor, but its reported inflammatory effects should not be conflated with evidence from recent Neuroligin 1 research. This overview separates established findings from interpretation and explains what the available evidence can—and cannot—support.

• Mapping Cholesterol Homeostasis with Filipin III

  2026-10-04

  A translational perspective on how Filipin III can complement mechanistic studies of cholesterol homeostasis, including the CAV1–FXR/ABCG5/ABCG8 axis implicated in MASLD progression.

• Dabigatran Etexilate: Oral Direct Thrombin Inhibition

  2026-10-03

  The 2011 clinical review by Blommel and Blommel presents dabigatran etexilate as a major pharmacologic advance: an orally administered prodrug that produces direct, reversible thrombin inhibition without the routine anticoagulation monitoring associated with vitamin K antagonists. Its practical significance lies in predictable pharmacology and broad clinical investigation, balanced against bleeding risk, gastrointestinal adverse effects, and dependence on renal function.

• Poly(A) Tailing as a Translational Lever

  2026-10-02

  A mechanistic and strategic guide to using enzymatic poly(A) tailing to improve RNA workflow control, interpret mitochondrial biology, and strengthen translational validation.

• Pregnenolone Carbonitrile: PXR Workflows

  2026-10-01

  Pregnenolone Carbonitrile is a practical rodent PXR agonist for connecting CYP3A regulation, xenobiotic clearance, and liver injury biology. Its utility extends from controlled cell assays to microbiota-aware sepsis and fibrosis workflows, provided species, solubility, and exposure variables are tightly managed.

• TMB in P. vivax Serology: Signal to Decision

  2026-10-01

  TMB, or 3,3′,5,5′-Tetramethylbenzidine, converts HRP-linked epitope recognition into a measurable color signal. This article explains how to design TMB-based P. vivax serology around analytical controls, asymptomatic-infection interpretation, and the practical limits of translating promising epitopes into surveillance assays.

• RP3-340N1.2, IL-6, and NSCLC Progression

  2026-09-30

  This reference study identifies the lncRNA RP3-340N1.2 as a post-transcriptional regulator of IL-6 mRNA stability in non-small cell lung cancer. Its combination of RNA sequencing, genetic perturbation, mRNA decay analysis, RNA immunoprecipitation, and macrophage co-culture links an RNA-binding protein mechanism to tumor-cell and microenvironmental phenotypes.

• Allosteric PDK4 Inhibitors for Metabolic Disease

  2026-09-30

  Jeon and colleagues identified anthraquinone-derived allosteric inhibitors of pyruvate dehydrogenase kinase 4, with compound 8c showing nanomolar biochemical potency and activity across metabolic, allergic, and cancer-related models. The study combines medicinal chemistry, pharmacokinetic assessment, molecular docking, and disease-relevant experiments to support a new scaffold for PDK4 inhibitor development.

8178 records 1/546 page Next 12345 下5页 Last page